Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic.
Adolescent
Biomarkers
/ analysis
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
COVID-19
/ complications
Child
Diabetes Mellitus, Type 1
/ drug therapy
Female
Follow-Up Studies
Glycemic Control
/ methods
Humans
Hypoglycemic Agents
/ therapeutic use
Italy
/ epidemiology
Longitudinal Studies
Male
Prognosis
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Telemedicine
COVID-19
children and adolescents
continuous glucose monitoring system
glycemic control
telemedicine—utilization
type 1 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
08
2020
accepted:
11
11
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
To minimize the wide spread of coronavirus disease (COVID-19) pandemic, Italy was placed in an almost complete lockdown state that forced people to "stay at home". Aim of this study was to evaluate the effects of lockdown on glycemic control in children and adolescents with type 1 diabetes (T1D) followed through telemedicine. This observational study involved patients with T1D using the real-time continuous glucose monitoring (CGM) Dexcom G6 Sixty-two children and adolescents (11.1 ± 4.37 years, 50% males) with T1D (median time disease 3.67 years) were enrolled in the study. Insulin total daily dose was unchanged, while time spent on physical activities was decreased (p<0.0001). Despite the lack of statistical significance, median value of the glucose management indicator decreased from 7.4% to 7.25%. Glucose standard deviation (p<0.0001) and coefficient of variation (p=0.001) improved across the study. Median time in range increased from 60.5% to 63.5% (p=0.008), time above range decreased from 37.3% to 34.1% (p=0.048), and time below range decreased from 1.85% to 1.45% (p=0.001). Overall, in our children and adolescents with T1D glycemic control improved during lockdown. Despite patients were confined to their homes and limited to exercise, our data suggest that the use of real-time CGM, the continuous parental management, and the telemedicine can display beneficial effects on T1D care.
Sections du résumé
Background/Objective
To minimize the wide spread of coronavirus disease (COVID-19) pandemic, Italy was placed in an almost complete lockdown state that forced people to "stay at home". Aim of this study was to evaluate the effects of lockdown on glycemic control in children and adolescents with type 1 diabetes (T1D) followed through telemedicine.
Subjects/Methods
This observational study involved patients with T1D using the real-time continuous glucose monitoring (CGM) Dexcom G6
Results
Sixty-two children and adolescents (11.1 ± 4.37 years, 50% males) with T1D (median time disease 3.67 years) were enrolled in the study. Insulin total daily dose was unchanged, while time spent on physical activities was decreased (p<0.0001). Despite the lack of statistical significance, median value of the glucose management indicator decreased from 7.4% to 7.25%. Glucose standard deviation (p<0.0001) and coefficient of variation (p=0.001) improved across the study. Median time in range increased from 60.5% to 63.5% (p=0.008), time above range decreased from 37.3% to 34.1% (p=0.048), and time below range decreased from 1.85% to 1.45% (p=0.001).
Conclusions
Overall, in our children and adolescents with T1D glycemic control improved during lockdown. Despite patients were confined to their homes and limited to exercise, our data suggest that the use of real-time CGM, the continuous parental management, and the telemedicine can display beneficial effects on T1D care.
Identifiants
pubmed: 33424771
doi: 10.3389/fendo.2020.595735
pmc: PMC7793913
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Hypoglycemic Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
595735Informations de copyright
Copyright © 2020 Predieri, Leo, Candia, Lucaccioni, Madeo, Pugliese, Vivaccia, Bruzzi and Iughetti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Diabetes. 2018 Oct;19 Suppl 27:302-325
pubmed: 30039513
Diabetes Technol Ther. 2020 Jun;22(6):462-467
pubmed: 32421355
Int J Clin Pract. 2016 Jul;70(7):569-76
pubmed: 27291327
Acta Diabetol. 2014 Apr;51(2):173-84
pubmed: 24162715
Diabetes Ther. 2020 May 11;:1-11
pubmed: 32395187
Diabetes Technol Ther. 2020 Jun;22(6):454-461
pubmed: 32396397
Pediatr Diabetes. 2014 May;15(3):175-89
pubmed: 23895512
J Diabetes Sci Technol. 2020 Jul;14(4):762-763
pubmed: 32460543
Curr Opin Endocrinol Diabetes Obes. 2015 Aug;22(4):265-9
pubmed: 26087340
Diabetes Care. 2020 Aug;43(8):e83-e85
pubmed: 32503837
Arch Dis Child. 2004 Feb;89(2):188-94
pubmed: 14736641
Diabetes Res Clin Pract. 2020 Aug;166:108297
pubmed: 32623042
J Endocrinol Invest. 2006 Jul-Aug;29(7):581-93
pubmed: 16957405
Pediatr Diabetes. 2018 Oct;19 Suppl 27:136-154
pubmed: 30062718
Pediatr Diabetes. 2018 Oct;19 Suppl 27:205-226
pubmed: 30133095
Pediatr Diabetes. 2020 May;21(3):413-414
pubmed: 32346988
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1213-1216
pubmed: 32679527
Diabetes Care. 2020 Aug;43(8):e88-e89
pubmed: 32540921
Diabetes Res Clin Pract. 2020 Aug;166:108307
pubmed: 32650036
Pediatr Diabetes. 2008 Apr;9(2):165-74
pubmed: 18416698
Diabetes Care. 2020 Jan;43(Suppl 1):S163-S182
pubmed: 31862756
J Diabetes Sci Technol. 2018 Mar;12(2):393-396
pubmed: 29334775
J Endocrinol Invest. 2020 Jun;43(6):867-869
pubmed: 32222956
J Clin Med. 2020 Jun 26;9(6):
pubmed: 32604895
J Clin Med. 2016 Nov 17;5(11):
pubmed: 27869655
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA Pediatr. 2020 Sep 1;174(9):882-889
pubmed: 32320004
J Sport Health Sci. 2020 Mar;9(2):103-104
pubmed: 32099716
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Transl Behav Med. 2020 Oct 8;10(4):819-826
pubmed: 32710626
Acta Paediatr Suppl. 2006 Apr;450:76-85
pubmed: 16817681
Pediatr Diabetes. 2018 Oct;19 Suppl 27:287-301
pubmed: 30084519
Pediatr Res. 2020 Jul 7;:
pubmed: 32634819
Front Pharmacol. 2017 May 30;8:330
pubmed: 28611672
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Diabet Med. 2019 Nov;36(11):1453-1459
pubmed: 31257642
J Clin Med. 2017 Feb 13;6(2):
pubmed: 28208807
Pediatr Diabetes. 2018 Dec;19(8):1459-1466
pubmed: 30129154
Pediatr Diabetes. 2020 Jul 20;:
pubmed: 32686287
Pediatr Diabetes. 2018 Oct;19 Suppl 27:115-135
pubmed: 29999222
Diabetes Care. 2015 Oct;38(10):1958-63
pubmed: 26404925
Diabetes Res Clin Pract. 2020 Aug;166:108302
pubmed: 32623034
Curr Diab Rep. 2018 May 24;18(7):42
pubmed: 29797292
Pediatr Diabetes. 2018 Oct;19 Suppl 27:105-114
pubmed: 30058221
J Pediatr Nurs. 2020 Jul - Aug;53:88-90
pubmed: 32317129
Diabetes Care. 2016 Dec;39(12):2126-2140
pubmed: 27879358
Diabetes Care. 2020 Sep;43(9):e111-e112
pubmed: 32690487
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
Diabetes Technol Ther. 2016 Jan;18(1):1-3
pubmed: 26756102
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Pediatr Pulmonol. 2020 Oct;55(10):2565-2575
pubmed: 32725955
Pediatr Clin North Am. 2015 Aug;62(4):873-88
pubmed: 26210622
J Pediatr. 1994 Aug;125(2):177-88
pubmed: 8040759
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Pediatr Diabetes. 2018 Oct;19 Suppl 27:237-249
pubmed: 30058247
BMJ Open Diabetes Res Care. 2020 Jun;8(1):
pubmed: 32503812